Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)

University of Kansas

Status and phase

Completed

Phase 2

Conditions

Polycystic Kidney Disease

Treatments

Other: Placebo

Dietary Supplement: Niacinamide

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT02558595

STUDY00002827

R21DK104086 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to observe the effects of niacinamide on markers of kidney injury, inflammation, kidney cyst growth and kidney function.

Full description

Polycystic Kidney Disease (PKD) is a genetic disease that affects about 1 in 500 people worldwide. It can lead to kidney failure which can lead to death. PKD causes the development of kidney cysts (fluid-filled balloons), which cause worsening kidney function. It is common for people with PKD to also have blood in the urine, kidney pain, high blood pressure, kidney stones, kidney infections, and cysts in the brain or other parts of the body.

There is currently no treatment known to stop cyst growth or a cure for the disease.

Participants in this study will be randomly assigned to one of two groups: niacinamide or placebo. Participants have an equal chance of being assigned to either of the groups. For people that qualify and decide to participate in this study, they will be asked to make five visits to the study clinic and complete two study related phone calls over the course of 12 months.

Enrollment

36 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed diagnosis of autosomal dominant polycystic kidney disease (ADPKD).
Estimated glomerular filtration rate (eGFR) > 50 ml/min/1.73m2 as determined from the serum creatinine by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
Provide Informed consent

Exclusion criteria

History of liver disease or abnormal liver function test
Heavy alcohol intake
Chronic diarrhea or malabsorption syndrome
Thrombocytopenia
Hypophosphatemia
Pregnancy or lactation or plan to become pregnant during the study
Treatment with anti-epileptic drugs
Treatment with tolvaptan, current or within 2 months prior to screening
Participation in another interventional trial currently or within 2 months prior to screening.

Exclusions specific to magnetic resonance (MR) imaging acquisition and measurement:

Partial or total nephrectomy or renal cyst reduction (including aspiration) done <1 year ago
Cardiac pacemaker.
Presence of MR incompatible metallic clips (e.g. clipped cerebral aneurysm)
Body weight >159 kg (350 lbs) or untreatable claustrophobia.